Products 2326521-71-3

CAS 2326521-71-3 appears in our catalog under these names: Adagrasib, Adagrasib/ 99.84% (existing batch purity), MRTX849, Adagrasib 98%, 2-Piperazineacetonitrile, 4-[7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-, 98%, 98%. Offered by: Chemat Brand, TargetMol, GLPBio, Biosynth, Ambeed. Available pack sizes: on request, 5mg, 10mg, 25mg, 50mg, 100mg, 500mg, 1g.

Adagrasib
Chemat Brand
  • size: on request
  • Variants: 1
View product
Adagrasib/ 99.84% (existing batch purity)
TargetMol
  • size: 5mg, 10mg, 25mg, 50mg
  • Variants: 6
from 571.74
View product
MRTX849
GLPBio, Biosynth
  • size: 10mg, 100mg, 1g, 25mg
  • Variants: 11
from 690.65
View product
Adagrasib 98%
Ambeed
  • size: 10mg, 25mg, 50mg, 100mg
  • Variants: 6
from 509.44
View product
2-Piperazineacetonitrile, 4-[7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-, 98%, 98%
Chemat
  • size: 5mg, 10mg, 100mg, 250mg
  • Variants: 6
from 198.80
View product
Adagrasib, 99.96%
MedChemExpress
  • size: 500 mg, 50 mg, 100 mg, 25 mg
  • Variants: 9
from 472.94
View product
Structural formula: {0} (CAS {1})

Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations.

Source: ChEBI

Identity
Molecular formulaC32H35ClFN7O2
Molecular weight604.1 g/mol
IUPAC name2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile
InChIKeyPEMUGDMSUDYLHU-ZEQRLZLVSA-N
SMILESCN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F

Computed by PubChem (NCBI)

Synonyms: Adagrasib, KRAZATI, Kras G12C inhibitor MRTX849, Adagrasib [USAN], Adagrasib (MRTX849), Krazati (TN), ADAGRASIB [INN], Adagrasib (USAN/INN), ADAGRASIB [WHO-DD], C32H35ClFN7O2